97 related articles for article (PubMed ID: 15372221)
1. A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients.
Jatoi A; Jett JR; Sloan J; Novotny P; Ford J; Prabhakar U; Loprinzi CL
Support Care Cancer; 2004 Dec; 12(12):859-63. PubMed ID: 15372221
[TBL] [Abstract][Full Text] [Related]
2. A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9).
Jatoi A; Ritter HL; Dueck A; Nguyen PL; Nikcevich DA; Luyun RF; Mattar BI; Loprinzi CL
Lung Cancer; 2010 May; 68(2):234-9. PubMed ID: 19665818
[TBL] [Abstract][Full Text] [Related]
3. A pilot trial of gefitinib in combination with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer.
Manegold C; Gatzemeier U; Buchholz E; Smith RP; Fandi A
Clin Lung Cancer; 2005 May; 6(6):343-9. PubMed ID: 15943894
[TBL] [Abstract][Full Text] [Related]
4. A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma.
Ross HJ; Hart LL; Swanson PM; Rarick MU; Figlin RA; Jacobs AD; McCune DE; Rosenberg AH; Baron AD; Grove LE; Thorn MD; Miller DM; Drachman JG; Rudin CM
Lung Cancer; 2006 Oct; 54(1):69-77. PubMed ID: 16934909
[TBL] [Abstract][Full Text] [Related]
5. Clinical and pharmacokinetic study of docetaxel in elderly non-small-cell lung cancer patients.
Takigawa N; Segawa Y; Kishino D; Fujiwara K; Tokuda Y; Seki N; Shinkai T; Watanabe Y; Hiraki S; Kozuki T; Gemba K; Tabata M; Kiura K; Ueoka H; Tanimoto M
Cancer Chemother Pharmacol; 2004 Sep; 54(3):230-6. PubMed ID: 15127232
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel (Taxotere) and vinorelbine in the treatment of non-small cell lung cancer.
Georgoulias V; Kourousis C; Androulakis N; Kakolyris S; Papadakis E; Bouros D; Apostolopoulou F; Georgopoulou T; Agelidou M; Souglakos J; Halkiadakis G; Hatzidaki D
Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-9-S14-14. PubMed ID: 9335517
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial.
Alexopoulos K; Kouroussis C; Androulakis N; Papadakis E; Vaslamatzis M; Kakolyris S; Samelis G; Patila E; Vossos A; Samantas E; Georgoulias V
Cancer Chemother Pharmacol; 1999; 43(3):257-62. PubMed ID: 9923557
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer.
Belani CP
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):42-5. PubMed ID: 9364542
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer.
William WN; Zinner RG; Karp DD; Oh YW; Glisson BS; Phan SC; Stewart DJ
J Thorac Oncol; 2007 Aug; 2(8):745-50. PubMed ID: 17762342
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer.
Millward MJ; Zalcberg J; Bishop JF; Webster LK; Zimet A; Rischin D; Toner GC; Laird J; Cosolo W; Urch M; Bruno R; Loret C; James R; Blanc C
J Clin Oncol; 1997 Feb; 15(2):750-8. PubMed ID: 9053501
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170
[TBL] [Abstract][Full Text] [Related]
12. Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer.
Ready N; Karaseva NA; Orlov SV; Luft AV; Popovych O; Holmlund JT; Wood BA; Leopold L
J Thorac Oncol; 2011 Apr; 6(4):781-5. PubMed ID: 21289522
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of combined modality therapy with concurrent topotecan plus radiotherapy followed by consolidation chemotherapy for unresectable stage III and selected stage IV non-small-lung cancer.
Seung SK; Ross HJ
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):802-9. PubMed ID: 18762390
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer.
Fossella FV; Lee JS; Shin DM; Calayag M; Huber M; Perez-Soler R; Murphy WK; Lippman S; Benner S; Glisson B
J Clin Oncol; 1995 Mar; 13(3):645-51. PubMed ID: 7884425
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics.
Morgan RJ; Doroshow JH; Synold T; Lim D; Shibata S; Margolin K; Schwarz R; Leong L; Somlo G; Twardowski P; Yen Y; Chow W; Lin P; Paz B; Chu D; Frankel P; Stalter S
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5896-901. PubMed ID: 14676112
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer.
Adjei AA; Argiris A; Murren JR
Semin Oncol; 1999 Oct; 26(5 Suppl 16):32-40; discussion 41-2. PubMed ID: 10585007
[TBL] [Abstract][Full Text] [Related]
17. U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy.
Larkins E; Scepura B; Blumenthal GM; Bloomquist E; Tang S; Biable M; Kluetz P; Keegan P; Pazdur R
Oncologist; 2015 Nov; 20(11):1320-5. PubMed ID: 26446239
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel in the treatment of advanced non-small-cell lung cancer.
Saloustros E; Georgoulias V
Expert Rev Anticancer Ther; 2008 Aug; 8(8):1207-22. PubMed ID: 18699760
[TBL] [Abstract][Full Text] [Related]
19. Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.
Karayama M; Inui N; Kuroishi S; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Suda T; Chida K
Cancer Chemother Pharmacol; 2013 Aug; 72(2):445-52. PubMed ID: 23807323
[TBL] [Abstract][Full Text] [Related]
20. The development of docetaxel (Taxotere) in non-small cell lung cancer--docetaxel in new combinations and new schedules: an overview of ongoing and future developments.
Donnellan PP; Crown JP
Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-18-S14-21. PubMed ID: 9335519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
